EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Outcomes of hyaluronic acid and dextrose prolotherapy on surgically induced rat osteoarthritis: Single versus combined treatment

Wael Amin Nasr El‐Din, Bhagath Kumar Potu, Raouf Abdelrahman Fadel, Islam Omar Abdel Fattah

The Anatomical Record · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Osteoarthritis (OA) is the most prevalent chronic joint disorder. This study explored therapeutic mechanisms of intra‐articular (i.a.) hyaluronic acid (HA), and/or dextrose prolotherapy (DPT) on surgically induced OA. Rats were divided into five groups ( n = 12): control, OA, HA, DPT, and DPT + HA groups. OA group revealed increase in serum alkaline phosphatase (ALP) level, knee extension angle diameter, and CD44 immuno‐expression, furthermore a decrease in cartilage thickness, chondrocyte density, and glycosaminoglycan and proteoglycan cartilage contents. Radiologically and microscopically, OA caused joint cavity narrowing, articular damage, exposed subchondral bone, and a rough surface. These parameters were modulated in HA, DPT, and DPT + HA groups. There were significant decreased ALP level (404.35, 414.97, and 318.73 U/L) (OA = 425.65 U/L), extension angle (29.25°, 47.93°, and 26.42°) (OA = 52.78°), knee diameter (7.52, 7.04, and 6.92 mm) (OA = 8.87 mm) and CD44‐immunopositive chondrocyte percentage (73.27%, 16.33%, and 83.40%) (OA = 87.95%), and increased cartilage thickness (155.24, 186.83, and 230.56 μm) (OA = 115.98 μm), chondrocyte density (2.24, 3.11, and 3.21 cell × 10 −3 /μm 2 ) (OA = 2.01 cell × 10–3/μm 2 ), and glycosaminoglycan (0.653, 0.837, and 0.886) (OA = 0.485) and proteoglycan cartilage contents (0.588, 0.710, and 0.738) (OA = 0.340). There was no significant difference between HA and DPT groups except for extension angle, chondrocyte density, and glycosaminoglycan and proteoglycan contents were higher in the HA group, and CD44‐immunoexpression was higher in the HA group. In conclusion, combination of i.a. HA and DPT has the upper hand in mitigation of OA parameters and is recommended for OA treatment.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Wael Amin Nasr El‐Din, Bhagath Kumar Potu, Raouf Abdelrahman Fadel, Islam Omar Abdel Fattah
Quelle
The Anatomical Record
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1932-8486, 1932-8494
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Wael Amin Nasr El‐Din, Bhagath Kumar Potu, Raouf Abdelrahman Fadel, Islam Omar Abdel Fattah (2026). Outcomes of hyaluronic acid and dextrose prolotherapy on surgically induced rat osteoarthritis: Single versus combined treatment. The Anatomical Record. https://doi.org/10.1002/ar.70345
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1 · Lizenz 2